Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
IN

NASDAQ · INCR

InterCure Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$5.17

Up+$0.14 (+2.78%)

Updated Oct 11, 2026, 8:50 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
67.8M
P/E ratio
-3.23
Dividend yield
0.00%
52-week range
$0.72 – $6.10
Volume
516.73
Avg. volume
58.85K

Price performance · INCR

INCR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

INCR closed at $5.17 after 20 trading sessions, down 2.27% for the selected period.

Last close
$5.17
Period change
-2.27%
Period low
$5.03
Period high
$5.47
Daily close
View OHLC price history
INCR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$5.17$5.17$5.17$5.17516.73
Oct 8, 2026$5.10$5.1156$5.02$5.033.26K
Oct 7, 2026$5.32$5.335$5.13$5.137.77K
Oct 6, 2026$5.30$5.32$5.30$5.322.62K
Oct 5, 2026$5.45$5.45$5.45$5.451.49K
Oct 2, 2026$5.3836$5.42$5.3801$5.422.76K
Oct 1, 2026$5.43$5.48$5.37$5.372.01K
Sep 30, 2026$5.37$5.38$5.23$5.2723.6K
Sep 29, 2026$5.10$5.33$5.10$5.232.27K
Sep 28, 2026$5.01$5.10$5.01$5.092.08K
Sep 25, 2026$5.10$5.26$5.02$5.218.86K
Sep 24, 2026$5.42$5.42$5.11$5.262.45K
Sep 23, 2026$5.38$5.47$5.25$5.475.25K
Sep 22, 2026$5.32$5.6799$5.28$5.3921.69K
Sep 21, 2026$5.245$5.245$5.245$5.245493
Sep 18, 2026$5.35$5.35$5.30$5.313.75K
Sep 17, 2026$5.315$5.315$5.24$5.311.23K
Sep 16, 2026$5.21$5.36$5.21$5.312.53K
Sep 15, 2026$5.1808$5.1808$5.13$5.132.32K
Sep 14, 2026$5.12$5.32$5.12$5.292.87K

Latest INCR news

The latest Smart Investors Daily articles mentioning INCR.

Stock researchCompany · Overview

INCR research

Overview

Company profile and research snapshot.

Company profile

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK and HERZLIYA, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) announced today that it received written confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The confirmation follows a written notification received b

Benzinga · Sep 8, 2026

InterCure Regains Nasdaq Compliance

InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) ("InterCure" or the "Company") announced today that it received written confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC

Yahoo · Aug 27, 2026

InterCure (INCR) Finalized a $77M Settlement, but How Much New Cash Will it Receive?

InterCure Ltd. (NASDAQ:INCR) finalized a NIS 230 million, or approximately $77 million, settlement with Israeli authorities covering indirect damages from the October 7, 2023 attacks and subsequent war. The more relevant figure for investors is approximately $43 million. The $77 million represents aggregate compensation rather than a new cash payment. InterCure Ltd. (NASDAQ:INCR) previously received […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By